Ryvu Therapeutics
Manufacturing · Poland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Leona Henryka Sternbacha 2, Krakow, Less...Phone Number
+48 123140200Website
www.ryvu.comRevenue
$35.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Ryvu Therapeutics
Ryvu Therapeutics is a clinical stage biopharmaceutical company focused on developing novel small molecule therapies for precision oncology. Their product pipeline includes innovative treatments aimed at overcoming clinical limitations in current oncology therapies, particularly through kinase inhibitors, synthetic lethality, and immuno-oncology programs. The company serves patients and stakeholders in the healthcare sector, striving to enhance treatment paradigms in oncology. Established in 2007 and publicly listed since 2014, Ryvu is committed to advancing breakthrough science for the benefit of its shareholders and partners.Explore more
Ryvu Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ryvu Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Ryvu Therapeutics had a recent Job posting/layoffs
Check out if Ryvu Therapeutics is spiking on competitors!
Check if Ryvu Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Ryvu Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Ryvu Therapeutics
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Ryvu Therapeutics recently announced quarterly report
Product Launch: Get notified when Ryvu Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Ryvu Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Ryvu Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ryvu Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ryvu Therapeutics.
Ryvu Therapeutics financials insights
Gather financial insights about Ryvu Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Unspecified
$22M
Share Placement
$57M
Ryvu Therapeutics Tech Stack
A closer look at the technologies used by Ryvu Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Earnings
Earnings, Finance
Open Position
Open Position
Open Position
Ryvu Therapeutics News & Media
Ryvu Therapeutics provides an update on RVU120 Phase II program
KRAKOW, Poland, Dec. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and data in the Phase II program RVU120, its...Ryvu Therapeutics Reports 2024 Q3 Financial Results and Provides Corporate Update
In Q1-Q3 2024, Ryvu recognized total operating revenues (including grants) of USD 18.6 million, compared to USD 11.9 million in Q1-Q3 2023. Ryvu reports an acceleration in patient enrollment for its RVU120 Phase II clinical studies, attributed in part to a significant increase in the...Ryvu Therapeutics to Collaborate with nCage Therapeutics on the Development of a Next-Generation ADC Platform
KRAKOW, Poland, Oct. 29, 2024 /PRNewswire/ -- Ryvu Therapeutics and nCage Therapeutics are pleased to announce that they have entered a research collaboration to develop a next-generation antibody-drug conjugate (ADC) platform. nCage has developed a TRAP cage platform where the protein...Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium
Ryvu presents four posters at the 2024 ENA Symposium: (a) RVU305 (MTA-cooperative PRMT5 inhibitor), demonstrating a potentially best-in-class profile, (b) WRN program, in lead optimization, (c) ONCO Prime platform, highlighting novel target discovery in synthetic lethality and (d) RVU120,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Ryvu Therapeutics
Sign Up For FreeTo access detailed company insights
Ryvu Therapeutics is a clinical stage biopharmaceutical company focused on developing novel small molecule therapies for precision oncology. Their product pipeline includes innovative treatments aimed at overcoming clinical limitations in current oncology therapies, particularly through kinase inhibitors, synthetic lethality, and immuno-oncology pr... Read More
